AGM 2018

Annual General Meeting 2018
Ascelia Pharma’s Annual General Meeting (Sw. årsstämma) was held at the premises of Setterwalls Advokatbyrå AB at Stortorget 23 in Malmö, Sweden on Friday 23 November 2018 at 11.00 a.m. Notice to the Annual General Meeting together with documents as per the agenda are found below.

 

Processing of personal data
The shares in Ascelia Pharma AB are registered at Euroclear Sweden AB (the Swedish Securities Register Center). For information on how your personal data is processed in Euroclear, see https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-GM-English.pdf

 

Minutes AGM 23 November 2018 (ENG translation)

 

Documents for AGM 2018:

Notice to AGM 2018

Power of Attorney template AGM 2018

Proposal and reasoned statement from the Nomination Committee (SWE and ENG version included)

Instruction and charter for the Nomination Committee (SWE and ENG version included)

Report by the board on variable remuneration to senior executives (SWE and ENG version included)

Remuneration guidelines (SWE and ENG version included)

Proposal for authorization regarding authorization for new issues (SWE and ENG version included)

Proposal regarding resolution on cancellation of warrants (SWE and ENG version included)

Proposal for resolution regarding implementation of employee option program (SWE and ENG version included)

Annual Report 2017-2018 (English version)

 

 

Mangoral

Our lead candidate Mangoral is a liver imaging drug (i.e. a liver specific contrast agent) being developed for detection and localization of potential liver metastases, using Magnetic Resonance Imaging (“MRI”) in patients where use of the current gold standard gadolinium-based contrast agents (“GBCAs”) may be medically inadvisable or cannot be administered. Mangoral is currently ready for Phase III clinical development.

Oncoral

Oncoral is a novel tablet-based formulation of the well-known chemotherapeutic agent irinotecan, intended for the treatment of advanced gastric (stomach) cancer. Irinotecan is today mainly used for treating metastasized colorectal cancer. Although irinotecan is currently not approved for treating gastric cancer in the United States and in the EU, there is off-label use for this indication. Oncoral is currently being evaluated in an investigator sponsored Phase I study.

DEVELOPMENT PLAN

Ascelia has established a development program for lead candidate Mangoral, consisting of a pivotal Phase III efficacy study and two supportive studies. The clinical development strategy for Oncoral, Ascelia´s second drug candidate, is to obtain Phase II data and then to partner for the further development.